A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Decoy Therapeutics Inc. operates as a pre-clinical stage biotechnology company. It focuses on advancing the peptide conjugate therapeutics through its Immediate Peptide/PPMO/P-PROTAC Alpha-helical Conjugate Technology (IMP3ACT) platform that leverages peptide coiled-coils chemistry and physics to design a-helical peptides through computational and ML tools. The company’s IMP3ACT platform leverages machine learning and artificial intelligence tools alongside synthesis techniques to engineer, enhance, and manufacture peptide conjugates targeting various unmet medical needs. It focuses on building a portfolio of peptide conjugate therapeutics focusing on infectious diseases and oncology. The company was formerly known as Salarius Pharmaceuticals, Inc. and change its name to Decoy Therapeutics Inc. in January 2026. Decoy Therapeutics Inc. is based in Houston, Texas.
Financial Summary
| Share Statistics | DCOY | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $2.2 | $252.6 | 1% |
|
| Shares Out (Mil) | 0.5 | 52.3 | 3% |
|
| Institutional Ownership | 67.8% | 92.1% | 42% |
|
| Float (Mil) | 0.5 | 40.2 | 1% |
|
| Beta | 0.58 | 0.95 | 33% |
|
| Avg Daily Volume (000s) | 136 | 455 | 39% |
|
| Price Change (52-week) |
(97.1%) | 52.9% | 2% |
|
| Growth | DCOY | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | (11.1%) | (9.9%) | 28% |
|
| EPS (5yr) | na | 16.0% | na |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | na | (15.6%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | DCOY | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $38 | na |
|
| Net Income (TTM) (Mil) | ($13) | ($43) | 27% |
|
| EPS (TTM) | ($57.120) | ($1.600) | 1% |
|
| Operating Cash Flow (TTM) (Mil) | ($7) | ($31) | 23% |
|
| Net Cash Flow (TTM) (Mil) | na | $5 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $5 | 0% |
|
| Enterprise Value (Q1) (Mil) | ($5) | $180 | 2% |
|
| Valuation | DCOY | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.56 | 2.56 | 10% |
|
| P/E | na | 19.0 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | DCOY | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 63.8% | na |
|
| Net Margin | na | (67.3%) | na |
|
| ROA | (242.2%) | (49.8%) | 1% |
|
| ROE | (661.7%) | (55.5%) | 1% |
|
| Liabilities to Assets | 54.0% | 30.3% | 46% |
|
| F-Score | 2 | 3 | na |
|
Decoy Therapeutics Inc. did not pass any screens on 7/31/2026.
